BiotechTube
BioFluidica

BioFluidica

San Diego, United States· Est.
biofluidica.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18.8M

Overview

BioFluidica is a pioneering liquid biopsy company with a versatile, automated platform that consolidates the isolation of multiple biomarker classes (cells, exosomes, cfDNA). Founded in 2007, the company has clinically validated its system across nine different cancer and prenatal sample types and operates both a product sales and a fee-for-service business model. While its instruments and services are currently for research use, the platform's demonstrated flexibility and ultralow sensitivity position it as a potential future tool for clinical diagnostics in precision medicine.

OncologyPrenatal Diagnostics

Technology Platform

LiquidScan: A fully automated microfluidic platform using immunoaffinity capture to isolate and enrich multiple liquid biopsy biomarkers (rare cells, exosomes, cfDNA) from blood and other biofluids in a single system.

Funding History

18
Total raised:$18.8M
Series A$8.5M
Grant$557K
Seed$2.5M
Grant$838K

Opportunities

The multi-analyte capability addresses a gap in the liquid biopsy market, potentially simplifying lab workflows.
The demonstrated ability to isolate intact fetal cells for prenatal testing presents a distinct competitive angle in the large NIPT market.
The established core lab and partnership model provides a pathway to generate revenue and validation data while building the clinical evidence base.

Risk Factors

Intense competition from larger, well-capitalized companies with established commercial products and sales channels.
Significant regulatory and clinical validation hurdles must be cleared to transition from a research tool to an approved diagnostic.
As a private company, reliance on external funding to finance costly clinical trials and commercial scaling presents ongoing financial risk.

Competitive Landscape

BioFluidica competes in the crowded liquid biopsy space against dominant players like Guardant Health (ctDNA-focused) and Bio-Techne (exosome-focused), as well as numerous CTC capture technology firms. Its key differentiation is the consolidation of multiple analyte types on one automated platform. However, it faces the challenge of competing with companies that have deeper commercial infrastructure and already market FDA-approved tests.

More companies in Diagnostics & Precision Medicine →More companies in United States →